W. Creutzfeldt

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

Michael A. Nauck, Markus M. Heimesaat, Jens J. Holst et al. · Journal of Clinical Investigation · 1993 · 1.6K citations · Full text

Glycobiology, Preserved Incretin Activity, Plasma Gip +18

Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes

Michael A. Nauck, F. Stöckmann, R. Ebert et al. · Diabetologia · 1986 · 1.3K citations · Full text

Obesity, Medicine, Insulin Management +6

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

Michael A. Nauck, N. Kleine, C. �rskov et al. · Diabetologia · 1993 · 1.1K citations · Full text

Metabolic Syndrome, Diabetes Management, Biochemistry +11

Incretin Effects of Increasing Glucose Loads in Man Calculated from Venous Insulin and C-Peptide Responses*

Michael A. Nauck, ERWIN HOMBERGER, E. G. Siegel et al. · The Journal of Clinical Endocrinology & Metabolism · 1986 · 866 citations

Early ERCP and Papillotomy Compared with Conservative Treatment for Acute Biliary Pancreatitis

Ulrich R. Fölsch, Rolf Nitsche, Rainer Lüdtke et al. · New England Journal of Medicine · 1997 · 607 citations